Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Hereditary Endometrial and Ovarian Cancers

  • Chapter
  • First Online:
Preventive Oncology for the Gynecologist

  • 510 Accesses

Abstract

Hereditary gynecological cancers including those of the endometrium and ovaries account for 5% and 12% of all these tumors, respectively. Hereditary cancers are suspected in women presenting with gynecological malignancies at a relatively young age or with a family history of cancer, usually of a specific cancer syndrome, in two or more relatives. The familial aggregation of cancers can be attributed to both genetic and environmental factors common within families, but genetic factors are thought to be more important. This chapter elaborates the genetic syndromes like hereditary nonpolyposis colorectal cancer (HNPCC) syndrome also known as Lynch syndrome, hereditary breast and ovarian cancer (HOBC) syndrome, Cowden syndrome, Li-Fraumeni syndrome, and Peutz-Jeghers syndrome, which are found to be responsible for majority of the hereditary gynecological malignancies. The screening guidelines along with the newer available diagnostic methods and treatment modalities based on the recent available evidence are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  CAS  PubMed  Google Scholar 

  2. Berends MJ, Wu Y, Sijmons RH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol. 2003;21:4364–70.

    Article  CAS  PubMed  Google Scholar 

  3. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–6.

    Article  CAS  PubMed  Google Scholar 

  4. Stratton JF, Pharoah PDP, Smith SK, Easton DF, Ponder BAJ. A systematic review an metaanalysis of family history an risk of ovarian cancer. Br J Obstet Gynaecol. 1998;105:493–9.

    Article  CAS  PubMed  Google Scholar 

  5. Gruber SB, Thompson WD. A population base study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomark Prev. 1996;5(6):411–7.

    CAS  Google Scholar 

  6. Lucenteforte E, Talamini R, Montella M, Dal Maso L, Pelucchi C, Franceschi S, La Vecchia C, Negri E. Family history of cancer and risk of endometrial cancer. Eur J Cancer Prev. 2009;18(2):95–9.

    Article  PubMed  Google Scholar 

  7. Parazzini F, Negri E, La Vecchia C, Restelli C, Francesci S. Family history of reproductive cancers and ovarian cancer risk: an Italian case control study. Am J Epidemiol. 1992;135(1):35–40.

    Article  CAS  PubMed  Google Scholar 

  8. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer- analyses of cohorts of twins from Sweden, Denmark, Finland. N Engl J Med. 2000;343(2):78–85.

    Article  CAS  PubMed  Google Scholar 

  9. Baker VV. Update on the molecular carcinogenesis of cervix cancer. Clin Consult Obstet Gynecol. 1995;7:86–93.

    Google Scholar 

  10. Hogdall EV, Christensen L, Kjaer SK, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003;98:66–73.

    Article  CAS  PubMed  Google Scholar 

  11. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304–11.

    CAS  PubMed  Google Scholar 

  12. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992;89:7491–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bacolod MD, Schemmann GS, Giardina SF, et al. Emerging paradigms in cancer genetics: some important findings from high-density single nucleotide polymorphism array studies. Cancer Res. 2009;69:723–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Meyer LA, Broadus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16(1):14–22.

    Article  PubMed  Google Scholar 

  15. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–8.

    Article  CAS  PubMed  Google Scholar 

  16. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary non polyposis colorectal cancer (HNPCC,Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453–6.

    Article  CAS  PubMed  Google Scholar 

  17. Watson P, Lynch HT. Cancer risk in mismatch repair genes mutation carriers. Familial Cancer. 2001;1:57–60.

    Article  CAS  PubMed  Google Scholar 

  18. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6(1):105–10.

    Article  CAS  PubMed  Google Scholar 

  19. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taaal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110(4):1020–7.

    Article  CAS  PubMed  Google Scholar 

  20. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Moller P, Genuardi M, van Houwelingen H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer ue to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004;127(1):17–25.

    Article  CAS  PubMed  Google Scholar 

  21. Hampel H, Stephens JA, Pukkala E, Sankila R, Aoltonen LA, Mecklin JP, de la Chapelle A. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005;129(20):415–21.

    Article  PubMed  Google Scholar 

  22. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, Vriends AH, Dutch Lynch Syndrome Study Group, Cartwright NR, Barnetson RA. Risk of LYNCH syndrome cancers in MSH6 mutation carriers. J Natl Cancer Inst. 2010;102(3):193–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, Myrhoj T, Sunde L, Wijnen JT, Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123(2):444–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Vasen HF, Stormorken A, Menko FH, Nageggast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary non polyposis colorectal cancer families. J Clin Oncol. 2001;19:4074–80.

    Article  CAS  PubMed  Google Scholar 

  25. Malander S, Rambech E, Kristoffersson U, Halvarsson B, Ridderheim M, Borg A, Nilbert M. The contribution of the hereditary non polyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol. 2006;101:238–43.

    Article  CAS  PubMed  Google Scholar 

  26. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J. BRCA1, BRCA 2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998;178:670–7.

    Article  CAS  PubMed  Google Scholar 

  27. Lu KH, Schorge JO, Roabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007;25:5158–64.

    Article  CAS  PubMed  Google Scholar 

  28. Berends MJ, Wu Y, Sijmons RH, van der Sluis T, Ek WB, Ligtenberg MJ, Arts NJ, ten Hoor KA, Kleibeuker JH, de Vries EG, et al. Toward new strategies to select endometrial cancer patients for mis-match repair gene mutation analysis. J Clin Oncol. 2003;21:4364–70.

    Article  CAS  PubMed  Google Scholar 

  29. Ollikainen M, Abdel-Rehman WM, M oisio AL, Lindroos A, Kariola R, Jarvela I, Poyhonen M, Butzow R, Peltomaki P. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol. 2005;23:4609–16.

    Article  CAS  PubMed  Google Scholar 

  30. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–23.

    Article  CAS  PubMed  Google Scholar 

  31. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–9.

    Article  CAS  PubMed  Google Scholar 

  32. Eng C. Will the real cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000;37:828–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Gayther SA, Russell P, Harrington P, Antoniou A, Easton DF, Ponder BAJ. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evience for other ovarian cancer susceptibility genes. Am J Hum Genet. 1999;65:1021–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ramus SJ, Harrington PA, Pye C, Dicioccio RA, Cox MJ, Garlinghouse-Jones K, Oakley-Girvan I, Jacobs IJ, Hardy RM, Whittemore AS, et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat. 2007;28(12):1207–15.

    Article  CAS  PubMed  Google Scholar 

  35. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet DD, Barjhoux L, Hughes DJ, et al. RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007;81(6):1186–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, et al. Common breast cancer predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82(4):937–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kurman RJ. Origin and molecular pathogenesis of ovarian high grade serous carcinoma. Ann Oncol. 2013;10:1016–21.

    Google Scholar 

  38. Kurman RJ, Shih IM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27(2):151–60.

    PubMed  PubMed Central  Google Scholar 

  39. Sama AR, Schilder RJ. Refractory fallopian tube carcinoma—current perspectives in pathogenesis and management. Int J Women’s Health. 2013;6(1):149–57.

    Google Scholar 

  40. Walsh T, Casadie S, Lee MK, Penil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massive parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer. 2010;20:704–16.

    Article  PubMed  Google Scholar 

  42. Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014;22(11):1305–13.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121(1):25–33.

    Article  CAS  PubMed  Google Scholar 

  44. Ruiz A, Llort G, Yagüe C, Baena N, Viñas M, Torra M, et al. Genetic testing in hereditary breast and ovarian Cancer using massive parallel sequencing. Biomed Res Int. 2014;2014:542541, 8 p

    PubMed  PubMed Central  Google Scholar 

  45. Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG. 2011;118:814–24.

    Article  CAS  PubMed  Google Scholar 

  46. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk- reducing salpingo- oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609–15.

    Article  PubMed  Google Scholar 

  47. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, van’t Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–22.

    Article  PubMed  Google Scholar 

  48. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331–7.

    Article  PubMed  Google Scholar 

  49. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185.

    Article  CAS  PubMed  Google Scholar 

  50. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, Menon U, Jacobs IJ. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol. 2013;31(1):49–57.

    Article  PubMed  Google Scholar 

  52. Dziadkowiec KN, Gąsiorowska E, Markwitz EN, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny. 2016;15(4):215–9.

    CAS  PubMed  Google Scholar 

  53. Sorrell AD, Espenschied CR, Culver JO, Weitzel JN. Tumor protein p53 (TP 53) testing and li-fraumeni syndrome: current status of clinical applications and future directions. Mol Diagn Ther. 2013;17(1):31–47.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643–50.

    CAS  PubMed  Google Scholar 

  55. Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol. 2006;4:408–15.

    Article  PubMed  Google Scholar 

  56. Hall MJ, Innocent J, Rybak C, Veloski C, Scott WJ, Wu H, et al. Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion. Appl Clin Genet. 2015;8:69–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Stratakis CA. Clinical genetics of multiple endocrine neoplasias, carney complex and related syndromes. J Endocrinol Investig. 2001;24:370–83.

    Article  CAS  Google Scholar 

  58. Jones B, Oh C, Mangold E, Egan CA. Muir–Torre syndrome: diagnostic and screening guidelines. Aust J Dermatol. 2006;47:266–9.

    Article  Google Scholar 

  59. Pancholi A, Collins D, Lindley R, Gandhi P. Muir–Torre syndrome: a case report and screening recommendations. Ann R Coll Surg Engl. 2008;90(8):W9–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Karanian-Philippe M, Velasco V, Longy M, Floquet A, Arnould L, Coindre JM, et al. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas. Am J Surg Pathol. 2015;39:1197–205.

    Article  PubMed  Google Scholar 

  61. Harrison ML, Hoskins P, du Bois A, Quinn M, Rustin GJ, Ledermann JA, Baron-Hay S, Friedlander ML. Small cell of the ovary, hypercalcemic type—analysis of combined experience and recommendation for management. A GCIG study. Gynecol Oncol. 2006;100:233–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

    Garima Yadav

  2. Department of Obstetrics and Gynaecology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India

    Anshuja Singla

Authors
  1. Garima Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anshuja Singla
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Babu Jagjivan Ram Memorial Hospital, New Delhi, India

    Sumita Mehta

  2. Department of Obstetrics and Gynecology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India

    Anshuja Singla

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yadav, G., Singla, A. (2019). Hereditary Endometrial and Ovarian Cancers. In: Mehta, S., Singla, A. (eds) Preventive Oncology for the Gynecologist. Springer, Singapore. https://doi.org/10.1007/978-981-13-3438-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-3438-2_4

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-3437-5

  • Online ISBN: 978-981-13-3438-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation